证券代码：603387 证券简称：基蛋生物 公告编号：2023-027 本次投资者说明会以网络互动形式召开，公司将针对 2023 年上半年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 09 月 12 日上午 10:00-11:00 基蛋生物科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于2023年09月05日(星期二)至09月11日(星期一)16:00前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱IR@getein.cn进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 基蛋生物科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 29 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上 半年度经营成果、财务状况，公司计划于 2 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-026 一、监事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第三届监事会第十一次会 议的通知已于2023年8月18日以电子邮件的方式发出，通知了全体监事和其他列 席人员。公司本次监事会会议于2023年8月28日以通讯表决方式召开。会议应到 监事人3人，实到监事3人；公司董事会秘书和财务负责人列席了本次监事会会议。 会议由监事会主席李靖召集和主持。本次会议召集、召开符合《中华人民共 和国公司法》及有关法律、法规和《公司章程》的规定。 二、监事会会议审议情况 （一）审议并通过《关于<公司2023年半年度报告>及其摘要的议案》 基蛋生物科技股份有限公司 第三届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司全体监事出席本次会议 是否有监事投反对或弃权票：否 本次监事会议案全部获得通过 监事会核查本项议案后认为：《公司2023年半年度报告》的编制和审议程序 符合法律、法规、《公司章程》和公司内部管理制度的 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-022 基蛋生物科技股份有限公司 关于 2023 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：向全体股东每10股派发人民币1元（含税）。 本次利润分配以实施权益分派股权登记日总股本数为基数，具体日期将 在权益分派实施公告中明确,在实施权益分派的股权登记日前公司总股本发生变 动的，拟维持分配总额不变，相应调整每股分配比例，并将另行公告具体调整情 况。 一、利润分配方案内容 基蛋生物科技股份有限公司（合并报表） 2023年1-6月实现净利润 171,580,000.10元，其中归属上市公司股东的净利润168,720,454.45元。2023年 半年度公司（合并报表）可供分配利润1,471,522,388.59元，母公司可供分配利 润1,249,703,008.38元（数据未经审计）。 基于对公司未来发展的良好预期，综合考虑公司经营现状、资产规模及盈余 情况，在保证公司正常经营和长远发展的前提下，为回报全 ...

Financial Performance - In 2022, the company achieved a net profit of RMB 503,944,698.54, with a net profit attributable to shareholders of RMB 498,909,980.40[6]. - The company proposed a cash dividend of RMB 3 per 10 shares, amounting to a total cash dividend of RMB 152,146,055.10, which represents 30.50% of the net profit attributable to shareholders[7]. - The total distributable profit for 2022 was RMB 1,454,947,989.25, after accounting for the profit distribution and retained earnings[6]. - The parent company reported a net profit of RMB 433,531,627.04 for 2022, with a total distributable profit of RMB 1,228,815,194.65[6]. - The company's operating revenue for 2022 reached ¥1,821,860,703.15, representing a year-on-year increase of 29.97%[25]. - The net profit attributable to shareholders for 2022 was ¥498,909,980.40, up 25.04% compared to the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 25.59% to ¥461,538,014.58[25]. - Basic earnings per share for 2022 were ¥0.98, an increase of 24.05% from ¥0.79 in 2021[26]. - The weighted average return on equity for 2022 was 21.76%, up from 20.43% in 2021[26]. - Total assets at the end of 2022 amounted to ¥3,677,437,948.24, reflecting a year-on-year growth of 17.19%[25]. Risk Management and Compliance - The company has outlined various risk factors that may affect its future development strategies and operational goals[10]. - The company has no non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures for external guarantees[10]. - The board of directors has ensured the authenticity, accuracy, and completeness of the annual report[4]. - The company received a standard unqualified audit report from Zhongtian Yun Accounting Firm[5]. Research and Development - The company achieved a research and development investment of 26,205.90 million yuan, a year-on-year increase of 40.19%, accounting for 14.38% of operating revenue[49]. - The number of R&D personnel increased to 632, up by 184 from the beginning of 2022[49]. - The company has 500 valid patents as of December 31, 2022, with 310 authorized patents, including 30 invention patents[49]. - The company has developed eight major technology platforms, including POCT, chemiluminescence, biochemical testing, and molecular diagnostics, enhancing its product system from single POCT products to a diverse range[70]. - The company is committed to continuous innovation in product development, focusing on unmet clinical needs[50]. Product Development and Market Expansion - The company launched several new products, including the MAGICL6200 fully automated chemiluminescence analyzer (400T/H) and the CM1000 fully automated biochemical analyzer (1000T/H)[50]. - The company launched the Metis600 emergency blood cell line, which integrates multiple testing capabilities for clinical needs, including blood routine, inflammation, cardiovascular, and glycation tests[40]. - The company is focusing on expanding its market share in grade hospitals by increasing penetration in previously untapped departments[38]. - The company has expanded its chemiluminescence product line to 78 items, including 11 cardiovascular projects, maintaining a leading position in the market[44]. - The company aims to further develop its product offerings in areas such as coagulation series and liver cancer screening, enhancing its competitive edge in the chemiluminescence market[46]. Marketing and Sales Strategy - The company implemented a dual-driven marketing reform strategy focusing on "core" and "collaboration" to enhance growth[52]. - The company has established a comprehensive after-sales service system with over 200 frontline engineers and 30 technical engineers nationwide[59]. - The company is focusing on proactive maintenance and upgrades for large instruments to improve customer satisfaction[59]. - The company aims to leverage new policies to enhance the construction of county-level medical institutions, benefiting the IVD sector[66]. - The company is focusing on expanding its direct sales team to enhance customer loyalty and market barriers[81]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with relevant laws and regulations[153]. - The supervisory board has 3 members, including 1 employee representative, fulfilling its duties to oversee financial conditions and major matters[154]. - The company has established a robust information disclosure system, ensuring timely and accurate communication of significant information to shareholders[155]. - The company maintains independent operations with complete assets, personnel, and financial systems, ensuring no conflicts of interest with controlling shareholders[156]. - The company has conducted 3 shareholder meetings during the reporting period, ensuring equal rights for all shareholders and no rejected resolutions[159]. Employee and Management Practices - The company has established a comprehensive welfare system for employees, including various benefits to enhance employee satisfaction and belonging[184]. - The company conducted training programs focusing on R&D processes, safety production, and management talent development during the reporting period[185]. - The company’s remuneration policy aims to align employee development with corporate interests, ensuring fair and competitive compensation[184]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 7.0898 million yuan[170]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB[167]. - The company plans to invest 200 million RMB in marketing to support the launch of new products and enhance brand visibility[167]. - The company aims to establish wholly-owned subsidiaries in Hong Kong, Singapore, and Germany, with plans to set up offices in Southeast Asia, South Asia, and Africa to deepen local market penetration[143]. - The company plans to increase R&D investment and strengthen technological innovation to enhance core competitiveness and improve operational performance[151].

Financial Performance - The company's operating revenue for Q1 2023 was ¥384,316,306.14, a decrease of 32.66% compared to the same period last year[2] - Net profit attributable to shareholders was ¥121,526,036.35, down 44.44% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥100,536,845.57, a decline of 54.32%[2] - Basic and diluted earnings per share were both ¥0.24, down 44.19% from the previous year[2] - Total operating revenue for Q1 2023 was ¥384,316,306.14, a decrease of 32.7% compared to ¥570,715,217.73 in Q1 2022[18] - Net profit for Q1 2023 was ¥124,371,119.11, a decline of 43.7% from ¥220,693,233.53 in Q1 2022[19] - The total comprehensive income for Q1 2023 was ¥124,267,374.11, down from ¥220,693,233.53 in Q1 2022[20] Cash Flow - The net cash flow from operating activities was ¥13,484,563.45, representing a significant drop of 79.84%[2] - In Q1 2023, the cash inflow from operating activities was CNY 528,041,082.97, a decrease of 21.1% compared to CNY 669,337,060.24 in Q1 2022[22] - The net cash flow from operating activities was CNY 13,484,563.45, down 79.9% from CNY 66,898,060.91 in the same period last year[22] - Cash inflow from investment activities totaled CNY 186,730,257.77, significantly up from CNY 42,531,695.56 in Q1 2022[22] - The net cash flow from investment activities was CNY 103,596,691.92, compared to a negative CNY 15,619,831.84 in Q1 2022[22] - Cash inflow from financing activities was CNY 297,813,000.00, down from CNY 376,609,940.27 in the previous year[23] - The net cash flow from financing activities was negative CNY 26,790,759.52, a decline from positive CNY 51,380,646.72 in Q1 2022[23] - The ending balance of cash and cash equivalents was CNY 732,976,882.93, down from CNY 1,045,222,484.13 at the end of Q1 2022[23] - The company reported a cash increase of CNY 88,332,104.53 in Q1 2023, compared to CNY 100,071,255.50 in Q1 2022[23] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,671,973,340.42, a slight decrease of 0.15% from the end of the previous year[3] - The company's total liabilities as of Q1 2023 amounted to ¥892,257,607.28, a decrease from ¥1,012,840,595.85 in the previous period[17] - The total equity attributable to shareholders was ¥2,603,189,418.94, an increase from ¥2,482,468,375.18 year-over-year[17] - Shareholders' equity attributable to the parent company increased by 4.86% to ¥2,603,189,418.94 compared to the end of the previous year[3] Revenue Breakdown - The decline in revenue was primarily attributed to a decrease in COVID-related business compared to the previous year[6] - In Q1 2023, the company achieved a revenue of 23.52 million RMB from COVID-related business, a significant decline of 93.11% year-on-year[10] - Excluding COVID revenue, the company's self-produced products generated a total revenue of 286.28 million RMB, marking a year-on-year increase of 71.69%[10] - The POCT product line reported a revenue of 213.16 million RMB, reflecting a year-on-year growth of 56.21%[11] - The sales revenue from the chemical luminescence product line reached 43.18 million RMB, showing a substantial increase of 277.64% year-on-year[11] Research and Development - The company continues to focus on R&D, aiming to enhance competitiveness across its IVD product lines[12] - Research and development expenses for Q1 2023 were ¥55,164,547.70, up from ¥50,924,275.03 in Q1 2022, indicating a focus on innovation[18] - The company plans to accelerate the market validation and coverage of the newly launched Metis6000 fully automated immunoassay line[11] Shareholder Information - The company had a total of 38,070 common shareholders at the end of the reporting period[8]

证券代码：603387 证券简称：基蛋生物 公告编号：2023-012 基蛋生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 05 月 18 日上午 09:00-10:00 会议召开时间：2023年05月18日(星期四)上午09:00-10:00 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 投资者可于2023年05月11日(星期四)至05月17日(星期三)16:00前登录 上证路演中心网站首页点击"提问预 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥403,956,352.10, representing a year-on-year increase of 25.50%[3] - The net profit attributable to shareholders for Q3 2022 was ¥145,399,343.30, reflecting a significant increase of 76.76% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥135,619,425.05, up by 83.96% year-on-year[3] - For the first three quarters of 2022, the company achieved a total revenue of 1.377 billion RMB, representing a year-over-year growth of 49.34%[11] - The net profit attributable to shareholders for the same period was 475 million RMB, an increase of 87.74% compared to the previous year[11] - Net profit for the first three quarters of 2022 was ¥481,071,216.93, representing a 83.5% increase from ¥262,123,493.95 in the same period of 2021[20] - The company reported a total comprehensive income of ¥481,643,628.87 for the third quarter of 2022, compared to ¥262,121,862.08 in the same quarter of 2021[21] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period increased by 113.33% to ¥207,880,331.23[3] - The net cash flow from operating activities for Q3 2022 was ¥207,880,331.23, an increase from ¥97,446,913.82 in Q3 2021, representing a growth of approximately 113%[24] - Total cash inflow from operating activities amounted to ¥1,456,238,026.02, compared to ¥1,106,288,768.88 in the previous year, indicating a year-over-year increase of about 32%[24] - Cash outflow from operating activities was ¥1,248,357,694.79, up from ¥1,008,841,855.06, reflecting a rise of approximately 24%[24] - The company’s cash and cash equivalents as of September 30, 2022, amounted to approximately 1.135 billion RMB, up from 968.9 million RMB at the end of 2021[15] - The cash and cash equivalents at the end of the period reached ¥1,133,577,261.76, up from ¥939,447,825.95 at the end of Q3 2021, representing an increase of approximately 21%[25] Assets and Equity - The total assets at the end of the reporting period were ¥3,654,181,309.98, a growth of 16.45% from the end of the previous year[4] - The equity attributable to shareholders at the end of the reporting period was ¥2,458,822,357.52, marking a 16.73% increase year-on-year[4] - Total assets as of September 30, 2022, were approximately 3.654 billion RMB, compared to 3.138 billion RMB at the end of 2021[16] - Total equity reached ¥2,641,369,078.62, up from ¥2,274,029,770.25 in the same period of 2021[18] Research and Development - Research and development investment for the first three quarters reached 170 million RMB, a year-over-year increase of 30.17%[13] - Research and development expenses for the first three quarters of 2022 were ¥151,894,491.01, an increase from ¥119,364,029.14 in the same period of 2021[19] Product Development and Market Strategy - The company attributed the revenue growth to the expansion of its product line and effective control of domestic COVID-19, leading to a significant increase in sales[6] - The company reported a year-to-date net profit growth driven by increased sales of self-produced products and improved cost control[6] - The company plans to launch several new products in Q4 2022, including the fully automated coagulation analyzer CA5200 and the high-speed fully automated chemiluminescence analyzer MAGICL6200[13] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] Inventory and Operating Costs - The company’s inventory increased to approximately 376 million RMB, up from 252 million RMB in the previous year[16] - Total operating costs for the first three quarters of 2022 were ¥847,993,776.91, up 30.6% from ¥649,303,464.59 in the previous year[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,376[8] - Basic and diluted earnings per share for the third quarter of 2022 were both ¥0.93, compared to ¥0.50 in the same quarter of 2021[21]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[12]. - The company's operating revenue for the first half of the year reached ¥973,211,496.78, representing a 62.12% increase compared to ¥600,288,159.94 in the same period last year[20]. - Net profit attributable to shareholders increased by 93.03% to ¥329,801,726.74 from ¥170,856,236.75 year-on-year[22]. - The net profit after deducting non-recurring gains and losses rose by 107.68% to ¥324,746,556.32 compared to ¥156,371,441.63 in the previous year[22]. - The company's cash flow from operating activities increased by 13.80% to ¥139,398,475.54, up from ¥122,489,994.89 in the same period last year[22]. - Basic earnings per share rose by 91.17% to ¥0.65 from ¥0.34 year-on-year[21]. - The company's total assets grew by 10.35% to ¥3,462,750,351.49 from ¥3,137,931,357.50 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 9.76% to ¥2,311,900,340.42 from ¥2,106,400,196.02 at the end of the previous year[20]. - The company achieved operating revenue of 973.21 million yuan, a year-on-year increase of 62.12%[51]. - The revenue from in vitro diagnostic business was 831 million yuan, reflecting a significant growth of 90.04%[51]. - The company reported a total operating profit of ¥341,905,801.15 for the first half of 2022, up from ¥150,030,047.62 in the same period of 2021, representing a growth of about 128.5%[140]. Market Expansion and Product Development - User data indicated an increase in active users by 25%, reaching a total of 5 million users by June 30, 2022[12]. - The company plans to launch three new products in the next quarter, focusing on point-of-care testing (POCT) technology[12]. - Market expansion efforts include entering two new international markets, aiming for a 10% increase in overseas sales by the end of 2022[12]. - The company is actively expanding its product lines and pursuing overseas strategies, contributing to revenue growth[22]. - The company is actively promoting new projects in various diagnostic areas, including myocardial markers, inflammation, and tumor markers[36]. - The company is focusing on market expansion, targeting a 30% increase in market share in key regions over the next two years[176]. - A strategic acquisition was announced, which is expected to contribute an additional 500 million in revenue annually starting next fiscal year[178]. - The company is exploring potential mergers and acquisitions to enhance its market share and operational capabilities[168]. Research and Development - The company is investing RMB 100 million in R&D for new diagnostic technologies, with a focus on enhancing product accuracy and speed[12]. - R&D investment for the first half of 2022 was 116.16 million yuan, representing a year-on-year increase of 45.73% and accounting for 11.93% of operating revenue[47]. - The company has established seven major technology platforms, enhancing its core competitiveness in the in vitro diagnostic industry[46]. - The company is committed to enhancing its R&D capabilities, focusing on small and high-speed chemiluminescence instruments and comprehensive reagent support[44]. - The company is actively researching and developing products for emerging health threats, such as monkeypox, and has completed EU registration for these products[37]. - The company has obtained 53 new product registration certificates in the first half of 2022, bringing the total to 1,209, including 359 domestic and 850 foreign certificates[56]. Operational Efficiency - The company has established a dynamic capacity adjustment mechanism to respond quickly to market demand, ensuring timely order fulfillment and maintaining reasonable inventory levels[38]. - The company emphasizes cost control through optimized supply chain management and has achieved favorable procurement costs, enhancing overall product competitiveness[37]. - The company has a robust production model that combines sales forecasting with a make-to-order approach, ensuring efficient production and inventory management[38]. - The company has implemented a flexible sales model that combines distribution and direct sales, enhancing its ability to innovate and respond to clinical demands[40]. Financial Management and Shareholder Commitments - The company reported a net cash outflow from investing activities of ¥45,355,737.88, a significant decrease of 141.61% from a net inflow of ¥109,010,969.85 in the previous period[60]. - The company has established commitments to avoid any potential competition from its actual controller and related parties[103]. - The controlling shareholder has pledged not to transfer shares for 36 months post-IPO, with specific conditions for any future share reductions[96]. - The company will notify the public three trading days in advance of any share reduction plans, including quantity and price range[100]. - The commitments made by shareholders and senior management are subject to public supervision and regulatory oversight[102]. Environmental and Social Responsibility - The company reported that it does not belong to the key pollutant discharge units and has implemented appropriate measures for environmental protection[82]. - The wastewater generated by the company meets the Class 3 standard of the Comprehensive Wastewater Discharge Standard (GB8979-1996) after pretreatment[83]. - The company has installed an online monitoring system for wastewater discharge, ensuring compliance with environmental standards[83]. - The company donated 644,000 RMB to the University of Science and Technology of China for COVID-19 crisis management training for medical personnel and related patients[89].

Financial Performance - In 2021, the company's POCT segment achieved revenue of 0.923 billion CNY, a 62% increase year-on-year [2] - The overall revenue growth reached 76%, with the immunology segment generating sales of 95.86 million CNY [2] - The hemostasis segment reported revenue of 40.24 million CNY, reflecting a 107% year-on-year growth [2] Market Strategy and Challenges - The company views centralized procurement as both a challenge and an opportunity, aiming to enhance market share and drive growth [3] - The company plans to leverage experiences from Anhui's centralized procurement to adapt to various forms of procurement reforms nationwide [3] Product Development and Feedback - The small luminescence product, Magicl6000, has received positive market feedback due to its compact size and high automation [3] - The company plans to launch a small automated production line by Q4 2022, integrating multiple instruments for combined testing [3][4] Future Plans and Innovations - The Getein1600 has been installed in over 6,000 units, with annual installations exceeding 1,000 [3] - The company is set to introduce the BHA-5100 fully automated blood cell analyzer and a new small production line in the second half of 2022 [4] - The development of the Getein3200 biochemical immunoassay analyzer aims to provide rapid results, with a target of 3 minutes for dry biochemical projects [4] Strategic Focus - The company emphasizes the importance of conventional product development for sustained performance growth, expanding into IVD across various fields [4] - There is a strategic shift towards high-end hospitals, with a focus on automation and quality control improvements [4]

2021 年年度报告 公司代码：603387 公司简称：基蛋生物 基蛋生物科技股份有限公司 2021 年年度报告 二零二二年四月 中国 南京 1 / 251 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 中天运会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人苏恩本、主管会计工作负责人倪文及会计机构负责人（会计主管人员）倪文声明： 保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经中天运会计师事务所（特殊普通合伙）审计，基蛋生物科技股份有限公司（合并报表）2021 年度实现净利润41,201.13万元，其中归属上市公司股东的净利润39,899.00万元，提取盈余公积 金3,144.11万元，加年初未分配利润84,816.89万元，减2020年已对股东分配的现金股利9,316.08 万元，2021年度公司累计可供分配利润112, ...